Get all your news in one place.

100's of premium titles.
One app.

Get all your news in one place.

100's of premium titles. One news app.

The Latest Breaking News from CareDx

CareDx Stock Is Up 300% Over the Past Year. Here’s How Much Upside Is Left.

CareDx (CDNA) has surged 300% over the past year, driven by robust technical momentum and strong buy signals. CDNA is rated a “Strong Buy” by several analysts, with consensus price targets suggesting up to 12% further upside. Revenue is projected to grow 30.38% this year, with earnings expected to rise...

CareDx Sharpens Precision Diagnostics Push With Naveris Deal, AlloHeme Plans

CareDx (NASDAQ:CDNA) executives outlined the company’s strategy to focus on precision diagnostics, expand into minimal residual disease testing and improve profitability during a Goldman Sachs-hosted discussion. Chief Executive Officer John Hanna said CareDx has reshaped its portfolio around areas

CareDx Highlights 39% Q1 Growth, Naveris Oncology Push at Jefferies

CareDx (NASDAQ:CDNA) executives outlined the company’s growth strategy, first-quarter performance and pipeline priorities during a presentation at the Jefferies Healthcare Conference, emphasizing transplant diagnostics, specialty oncology and digital workflow integration. John Hanna, chief executiv

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

CareDx Battles Reimbursement Uncertainty As Market Overlooks Long-Term Potential

CareDx, Inc. (NASDAQ:CDNA) faces fresh uncertainty as proposed reimbursement changes threaten its core testing business, clouding near-term growth even as the company’s expanding transplant solutions platform positions it for long-term opportunity in an $8 billion market.

Benzinga Before The Bell: Tesla Sues Louisiana Automobile Dealers Association, Will iPhone 14 Feature Satellite Connectivity?, Netflix Denies $7 To $9 Ad-Supported Plan And Other Top Financial Stories Tuesday, August 30

Reuters Taiwan’s China Airlines Orders 16 Boeing 787s

CareDx's Return On Capital Employed Overview

CareDx (NASDAQ:CDNA) brought in sales totaling $79.42 million during Q1 according to data provided by Benzinga Pro. However, earnings decreased 21.65%, resulting in a loss of $19.65 million.

CareDx: Q1 Earnings Insights

CareDx (NASDAQ:CDNA) reported its Q1 earnings results on Thursday, May 5, 2022 at 04:00 PM. Here's what investors need to know about the announcement. Earnings CareDx missed estimated earnings by 160.0%, reporting an EPS of $-0.13 versus an estimate of $-0.05.

inkl

Read news from The Economist, FT, and more,
with one subscription

Benzinga's Top Ratings Upgrades, Downgrades For April 25, 2022

Benzinga's Top Ratings Upgrades, Downgrades For April 25, 2022

Recap: CareDx Q4 Earnings

Recap: CareDx Q4 Earnings

CareDx (NASDAQ:CDNA) reported its Q4 earnings results on Thursday, February 24, 2022 at 04:00 PM. Here's what investors need to know about the announcement. Earnings CareDx missed estimated earnings by 200.0%, reporting an EPS of $-0.03 versus an estimate of $0.03.

1

People

Vitalik Buterin

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

Organisations

Wall Street Journal

Advanced Micro Devices

inkl

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

416,779 stories

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.

Download on the AppStore

Get it on Google Play